Sugi Predict

Sugi Predict / Compounds / SCHEMBL3669650

SCHEMBL3669650

SCHEMBL3669650

COC(=O)[C@]1(C)C[C@@H](O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ EPHX2 P34913 1/20 0.35
▸ HSD11B1 P28845 2/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ KDM1A O60341 1/20 0.32
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ EPHX1 P07099 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ HCRTR2 O43614 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19214900 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL15212838 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL27219245 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL20813371 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL15212714 1.00 CHRM2 (0.39) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL15913256 0.91 CHRM2 (0.41) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL3679572 0.91 CHRM2 (0.41) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL4769152 0.91 CHRM2 (0.41) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL19477954 0.87 HSD11B1 (0.36) CHRM2CHRM1CHRM3EPHX2HSD11B1
SCHEMBL12314347 0.87 HSD11B1 (0.36) CHRM2CHRM1CHRM3EPHX2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3245198-B1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS NOVARTIS AG (CH) 2020-03-11 — — EP disclosed
EP-3074384-B1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-05-22 — — EP disclosed
US-10065943-B2 Pyrrolidine derivatives as angiotensin II type 2 antagonists NOVARTIS AG (CH) 2018-09-04 — — US disclosed
US-20170369473-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-12-28 — — US disclosed
US-20170369473-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS SPINIFEX PHARMACEUTICALS PTY LTD (AU) 2017-12-28 — — US disclosed
EP-3245198-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS Novartis AG (CH) 2017-11-22 — — EP disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 — — US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 — — US disclosed
EP-3074384-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2016-10-05 — — EP disclosed
US-9403805-B2 Antiviral compounds HOFFMANN-LA ROCHE INC. (US) 2016-08-02 — — US disclosed
EP-2240475-B1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS NOVARTIS AG (CH) 2013-09-25 — — EP disclosed
WO-2013124335-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2013-08-29 — — WO disclosed
WO-2013124335-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2013-08-29 — — WO disclosed
EP-2240475-A1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS Novartis AG (CH) 2010-10-20 — — EP disclosed
WO-2009080694-A1 THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS NOVARTIS AG (CH) 2009-07-02 — — WO disclosed
US-20090163469-A1 Organic Compounds NOVARTIS AG 2009-06-25 — — US disclosed
US-6710064-B2 FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES BRISTOL-MYERS SQUIBB CO. 2004-03-23 — — US disclosed
EP-1339718-A1 HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS Bristol-Myers Squibb Company (US) 2003-09-03 — — EP disclosed
US-20020143035-A1 Hydantoin compounds useful as anti-inflammatory agents BRISTOL-MYERS SQUIBB COMPANY 2002-10-03 — — US disclosed
WO-2002044181-A1 HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369473-A1 PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS AGTR2, AGTR1, AVPR2 CHRM2 616/4885CHRM1 1539/4885CHRM3 1501/4885
US-10065943-B2 Pyrrolidine derivatives as angiotensin II type 2 antagonists AGTR2, AGTR1, ACE2 CHRM2 468/4885CHRM1 1216/4885CHRM3 1217/4885
US-20020143035-A1 Hydantoin compounds useful as anti-inflammatory agents HRH4, IL4I1, HRH2 CHRM2 827/4885CHRM1 446/4885CHRM3 1656/4885
US-20090163469-A1 Organic Compounds PIK3C3, PIK3CA, PIK3CD CHRM2 4830/4885CHRM1 4703/4885CHRM3 4481/4885
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GLP1R CHRM2 367/4885CHRM1 708/4885CHRM3 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.